GLP1R and liver dysplastic nodule: Current standard DN therapy consisting of antihypertensive, antidyslipidemic, and new anti-hyperglycemic agents, such as sodium-glucose cotransporter inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA), have been shown to slow the progression of the renal damage and reduce DN-related mortality [11,12].